RaQualia Pharma Inc. Logo

RaQualia Pharma Inc.

An R&D firm discovering novel small molecules for out-licensing to pharma partners.

4579 | T

Overview

Corporate Details

ISIN(s):
JP3967150008
LEI:
Country:
Japan
Address:
名古屋市中村区名駅南一丁目21番19号
Sector:
Mining and quarrying
Industry:
Mining of non-ferrous metal ores

Description

RaQualia Pharma Inc. is a research and development-focused drug discovery company that originated as a spin-off from Pfizer's research laboratories. The company specializes in the discovery and early-stage development of novel pharmaceutical compounds, or 'seeds' for new drugs, with a focus on small molecules. Its primary business model involves creating these development compounds and then generating revenue through out-licensing agreements and partnerships with other pharmaceutical companies for late-stage development and commercialization. RaQualia actively leverages an open collaboration network with academic and industry partners to advance its pipeline. The company is also expanding into new therapeutic modalities, such as targeted protein degradation, to address previously 'undruggable' targets.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-08-14 08:58
Report Publication Announcement
確認書
Japanese 8.2 KB
2025-08-14 08:57
Interim Report
半期報告書-第18期(2025/01/01-2025/12/31)
Japanese 229.8 KB
2025-04-18 08:30
Major Shareholding Notification
臨時報告書
Japanese 21.1 KB
2025-03-31 09:01
Registration Form
訂正有価証券届出書(参照方式)
Japanese 155.4 KB
2025-03-31 08:31
Registration Form
訂正確認書
Japanese 8.2 KB
2025-03-31 08:30
Annual Report
訂正有価証券報告書-第17期(2024/01/01-2024/12/31)
Japanese 811.9 KB
2025-03-26 08:05
Regulatory News Service
訂正有価証券届出書(参照方式)
Japanese 158.4 KB
2025-03-26 07:52
Post-Annual General Meeting Information
臨時報告書
Japanese 22.7 KB
2025-03-26 07:51
Registration Form
確認書
Japanese 8.2 KB
2025-03-26 07:50
Governance Information
内部統制報告書-第17期(2024/01/01-2024/12/31)
Japanese 23.1 KB
2025-03-26 07:49
Annual Report
有価証券報告書-第17期(2024/01/01-2024/12/31)
Japanese 1.4 MB
2025-03-21 07:30
Registration Form
有価証券届出書(参照方式)
Japanese 282.6 KB
2024-12-13 08:00
Board/Management Information
臨時報告書
Japanese 20.7 KB
2024-10-01 09:04
Share Issue/Capital Change
訂正臨時報告書
Japanese 35.8 KB
2024-09-13 08:31
Share Issue/Capital Change
臨時報告書
Japanese 37.9 KB

Automate Your Workflow. Get a real-time feed of all RaQualia Pharma Inc. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for RaQualia Pharma Inc.

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for RaQualia Pharma Inc. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

NRGene Technologies Ltd. Logo
AI-powered genomic analysis software to accelerate and optimize plant and animal breeding.
Israel
NRGN
Nuvectis Pharma, Inc. Logo
Clinical-stage biopharma developing precision medicines for serious oncological conditions.
United States of America
NVCT
Nykode Therapeutics ASA Logo
Developing novel immunotherapies and vaccines for cancer with its antigen-targeting platform.
Norway
NYKD
Ocugen, Inc. Logo
Develops gene/cell therapies and vaccines, specializing in blindness and public health.
United States of America
OCGN
Oculis Holding AG Logo
Clinical-stage biopharma developing non-invasive eye drops for sight-threatening diseases.
Switzerland
OCS
OKYO Pharma Ltd Logo
Biopharma developing novel drugs for inflammatory eye diseases and neuropathic corneal pain.
United States of America
OKYO
OLIPASS CORPORATION Logo
Biotech firm developing RNA therapeutics for diseases with its proprietary OPNA platform.
South Korea
244460
A technology platform for pharma/biotech to discover therapeutic antibodies via transgenic animals.
United States of America
OABIW
Oncocross Co.,Ltd. Logo
AI-powered biotech accelerating drug development for cancer and rare diseases.
South Korea
382150
Onconic Therapeutics Inc. Logo
Develops novel drugs for cancer and GI diseases, including a next-gen acid blocker.
South Korea
476060

Talk to a Data Expert

Have a question? We'll get back to you promptly.